Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 4/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.32 |
| ▸ | WNT1 | P04628 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21597926 | 0.90 | CHRM1 (0.63) | CHRM1DRD2CHRM2CHRM4 | |
| SCHEMBL27176055 | 0.89 | CHRM1 (0.49) | CHRM1DRD2GSK3BDYRK1AWNT1 | |
| SCHEMBL22472937 | 0.85 | CHRM1 (0.55) | CHRM1DRD2 | |
| SCHEMBL15618571 | 0.81 | CHRM1 (0.68) | CHRM1CHRM2CHRM4 | |
| SCHEMBL15618702 | 0.80 | CHRM1 (0.70) | CHRM1CHRM2CHRM4 | |
| SCHEMBL22472868 | 0.78 | MAPT (0.43) | CHRM1 | |
| SCHEMBL15630295 | 0.78 | CHRM1 (0.55) | CHRM1DRD2CHRM2CHRM4 | |
| SCHEMBL22472877 | 0.77 | SMN1; SMN2 (0.38) | CHRM1GSK3BDYRK1AWNT1KMT2A | |
| SCHEMBL22472933 | 0.77 | HPGD (0.44) | CHRM1KMT2A | |
| SCHEMBL15630227 | 0.76 | CHRM1 (0.53) | CHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585143-B | Bridging compounds as agonists of muscarinic M1 and/or M4 receptors | 奈克斯拉制药英国有限公司 | 2024-11-12 | — | — | CN | claimed |
| EP-3810614-B1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | claimed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885DRD2 200/4885GSK3B 2143/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885DRD2 200/4885GSK3B 2143/4885 |
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885DRD2 200/4885GSK3B 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.